Von Willebrand factor regulation in patients with acute and chronic cerebrovascular disease: a pilot, case-control study.
BACKGROUND AND PURPOSE: In animal models, von Willebrand factor (VWF) is involved in thrombus formation and propagation of ischemic stroke. However, the pathophysiological relevance of this molecule in humans, and its potential use as a biomarker for the risk and severity of ischemic stroke remains...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4061052?pdf=render |
| _version_ | 1818960971633262592 |
|---|---|
| author | Peter Kraft Christiane Drechsler Ignaz Gunreben Bernhard Nieswandt Guido Stoll Peter Ulrich Heuschmann Christoph Kleinschnitz |
| author_facet | Peter Kraft Christiane Drechsler Ignaz Gunreben Bernhard Nieswandt Guido Stoll Peter Ulrich Heuschmann Christoph Kleinschnitz |
| author_sort | Peter Kraft |
| collection | DOAJ |
| description | BACKGROUND AND PURPOSE: In animal models, von Willebrand factor (VWF) is involved in thrombus formation and propagation of ischemic stroke. However, the pathophysiological relevance of this molecule in humans, and its potential use as a biomarker for the risk and severity of ischemic stroke remains unclear. This study had two aims: to identify predictors of altered VWF levels and to examine whether VWF levels differ between acute cerebrovascular events and chronic cerebrovascular disease (CCD). METHODS: A case-control study was undertaken between 2010 and 2013 at our University clinic. In total, 116 patients with acute ischemic stroke (AIS) or transitory ischemic attack (TIA), 117 patients with CCD, and 104 healthy volunteers (HV) were included. Blood was taken at days 0, 1, and 3 in patients with AIS or TIA, and once in CCD patients and HV. VWF serum levels were measured and correlated with demographic and clinical parameters by multivariate linear regression and ANOVA. RESULTS: Patients with CCD (158 ± 46%) had significantly higher VWF levels than HV (113 ± 36%, P<0.001), but lower levels than AIS/TIA patients (200 ± 95%, P<0.001). Age, sex, and stroke severity influenced VWF levels (P<0.05). CONCLUSIONS: VWF levels differed across disease subtypes and patient characteristics. Our study confirms increased VWF levels as a risk factor for cerebrovascular disease and, moreover, suggests that it may represent a potential biomarker for stroke severity, warranting further investigation. |
| first_indexed | 2024-12-20T12:06:01Z |
| format | Article |
| id | doaj.art-7e77ce3f2ec6402f8d17b7bdf52dacae |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-20T12:06:01Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-7e77ce3f2ec6402f8d17b7bdf52dacae2022-12-21T19:41:24ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0196e9985110.1371/journal.pone.0099851Von Willebrand factor regulation in patients with acute and chronic cerebrovascular disease: a pilot, case-control study.Peter KraftChristiane DrechslerIgnaz GunrebenBernhard NieswandtGuido StollPeter Ulrich HeuschmannChristoph KleinschnitzBACKGROUND AND PURPOSE: In animal models, von Willebrand factor (VWF) is involved in thrombus formation and propagation of ischemic stroke. However, the pathophysiological relevance of this molecule in humans, and its potential use as a biomarker for the risk and severity of ischemic stroke remains unclear. This study had two aims: to identify predictors of altered VWF levels and to examine whether VWF levels differ between acute cerebrovascular events and chronic cerebrovascular disease (CCD). METHODS: A case-control study was undertaken between 2010 and 2013 at our University clinic. In total, 116 patients with acute ischemic stroke (AIS) or transitory ischemic attack (TIA), 117 patients with CCD, and 104 healthy volunteers (HV) were included. Blood was taken at days 0, 1, and 3 in patients with AIS or TIA, and once in CCD patients and HV. VWF serum levels were measured and correlated with demographic and clinical parameters by multivariate linear regression and ANOVA. RESULTS: Patients with CCD (158 ± 46%) had significantly higher VWF levels than HV (113 ± 36%, P<0.001), but lower levels than AIS/TIA patients (200 ± 95%, P<0.001). Age, sex, and stroke severity influenced VWF levels (P<0.05). CONCLUSIONS: VWF levels differed across disease subtypes and patient characteristics. Our study confirms increased VWF levels as a risk factor for cerebrovascular disease and, moreover, suggests that it may represent a potential biomarker for stroke severity, warranting further investigation.http://europepmc.org/articles/PMC4061052?pdf=render |
| spellingShingle | Peter Kraft Christiane Drechsler Ignaz Gunreben Bernhard Nieswandt Guido Stoll Peter Ulrich Heuschmann Christoph Kleinschnitz Von Willebrand factor regulation in patients with acute and chronic cerebrovascular disease: a pilot, case-control study. PLoS ONE |
| title | Von Willebrand factor regulation in patients with acute and chronic cerebrovascular disease: a pilot, case-control study. |
| title_full | Von Willebrand factor regulation in patients with acute and chronic cerebrovascular disease: a pilot, case-control study. |
| title_fullStr | Von Willebrand factor regulation in patients with acute and chronic cerebrovascular disease: a pilot, case-control study. |
| title_full_unstemmed | Von Willebrand factor regulation in patients with acute and chronic cerebrovascular disease: a pilot, case-control study. |
| title_short | Von Willebrand factor regulation in patients with acute and chronic cerebrovascular disease: a pilot, case-control study. |
| title_sort | von willebrand factor regulation in patients with acute and chronic cerebrovascular disease a pilot case control study |
| url | http://europepmc.org/articles/PMC4061052?pdf=render |
| work_keys_str_mv | AT peterkraft vonwillebrandfactorregulationinpatientswithacuteandchroniccerebrovasculardiseaseapilotcasecontrolstudy AT christianedrechsler vonwillebrandfactorregulationinpatientswithacuteandchroniccerebrovasculardiseaseapilotcasecontrolstudy AT ignazgunreben vonwillebrandfactorregulationinpatientswithacuteandchroniccerebrovasculardiseaseapilotcasecontrolstudy AT bernhardnieswandt vonwillebrandfactorregulationinpatientswithacuteandchroniccerebrovasculardiseaseapilotcasecontrolstudy AT guidostoll vonwillebrandfactorregulationinpatientswithacuteandchroniccerebrovasculardiseaseapilotcasecontrolstudy AT peterulrichheuschmann vonwillebrandfactorregulationinpatientswithacuteandchroniccerebrovasculardiseaseapilotcasecontrolstudy AT christophkleinschnitz vonwillebrandfactorregulationinpatientswithacuteandchroniccerebrovasculardiseaseapilotcasecontrolstudy |